Effect of Helicobacter pylori infection on the first-line treatment outcomes in patients with immune thrombocytopenic purpura
Yükleniyor...
Dosyalar
Tarih
2022
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Verduci Editore s.r.l
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
OBJECTIVE: Helicobacter pylori (H. pylori) eradication therapy is known to increase the platelet count, but in immune thrombocytopenic purpura (ITP), the effect of H. pylori infection on the response to treatment is not clear. This study aims to determine whether the response to the first-line treatment is affected by the states of H. pylori-positivity and -negativity in ITP patients. PATIENTS AND METHODS: Adult newly diagnosed or chronic ITP patients who had not received eradication therapy for H. pylori infection were included. Characteristics of the patients, presence and severity of bleeding, initial platelet count, administered treatments, and treatment response rates were inspected. RESULTS: Of 119 total patients, 66 (55.5%) were female, 32 (26.9%) were H. pylori-positive, 87 (73.1%) were H. pylori-negative. H. pylori-positive and H. pylori- negative groups were not significantly different in terms of age (p=0.127), gender (p=0.078), diagnosis status (p=0.094) and the distribution of bleeding symptoms (p=0.712). The most common treatment was standard-dose steroid in both groups (62.5% vs. 68.9%, p=0.524). Rates of complete response, partial response, no response were comparable for the two groups (respectively, 75% vs. 73.6%, and 18.8% vs. 19.5%, and 6.2% vs. 6.9%), and there was no significant difference between the groups (p=0.283). CONCLUSIONS: It can be stated, according to the present study, that in ITP patients in whom treatment is indicated, the response to the firstline treatment without the administration of H. pylori eradication therapy is similar between H. pylori-positive and H. pylori-negative patients. © 2022 Verduci Editore s.r.l. All rights reserved.
Açıklama
Anahtar Kelimeler
First-Line Treatment, Helicobacter Pylori, Immune Thrombocytopenic Purpura
Kaynak
European Review for Medical and Pharmacological Sciences
WoS Q Değeri
Scopus Q Değeri
Q2
Cilt
26
Sayı
11
Künye
Dogan, A., Ekinci, O., & Ebinc, S. (2022). Effect of helicobacter pylori infection on the first-line treatment outcomes in patients with immune thrombocytopenic purpura. European Review for Medical and Pharmacological Sciences, 26(11), 3995-4000. doi:10.26355/eurrev_202206_28970
